Simris Biologics

Simris Biologics is a Hamburg-based biotech subsidiary of the Simris Group, pioneering the use of cyanobacteria to develop novel payloads for Antibody-Drug Conjugates (ADCs). Its core asset is a proprietary platform that modifies cyanobacterial toxins to create highly potent, targeted cancer therapeutics with an improved safety profile, alongside a commercial business line of diagnostic standards. The company is pre-clinical, seeking early-stage licensing deals with biopharma partners to advance its pipeline, which is anchored by a lead microcystin variant candidate. Its strategy combines sustainable sourcing from the world's largest cyanobacterial strain library with a focus on unlocking the full therapeutic potential of ADCs.

Proprietary platform leveraging the world's largest cyanobacterial strain library (>5,000 compounds) to discover and bioengineer novel toxins. Patented methodology for in vivo structural modification of cyanobacterial non-ribosomal peptides (e.g., microcystins) to create targeted ADC payloads with high potency and improved safety profiles.

Simris competes in the novel ADC payload space against numerous biotechs and large pharma companies developing next-generation warheads (e.g., PBDs, duocarmycins, novel topoisomerase inhibitors). Its differentiation lies in its sustainable sourcing from a unique cyanobacterial library and its in vivo bioengineering platform. It also faces indirect competition from companies developing alternative targeted oncology modalities like bispecific antibodies and radiopharmaceuticals.